Associate Professor, Medicine, University of Washington School of Medicine
Oncology
Dr. Evan Y. Yu, MD
|
|
Give Review
Dr. Evan Y. Yu is an expert in the field of Oncology. He graduated from University of Washington School of Medicine. He received awards:"Regional Top Doctor". Evan is a published doctor. He has 32 papers published. The most current publication "Persistent androgen receptor addiction in castration-resistant prostate cancer." Evan is registered with Medicare.
Publications
- Castration-Resistant Prostate Cancer Bone Metastasis Response Measured by 18F-Fluoride PET After Treatment with Dasatinib and Correlation with Progression-Free Surviva...
- Activity of enzalutamide in men with metastatic castration-resistant prostate Cancer is affected by prior treatment with abiraterone and/or docetaxel.
- Quantitative and stoichiometric Analysis of the microRNA content of exosomes.
- Delayed Antiandrogen Withdrawal Syndrome After Discontinuation of Bicalutamide.
- Relationships Between Times to Testosterone and ProState-Specific Antigen Rises During the First Off-Treatment Interval of Intermittent Androgen Deprivation are Progno...
- Long-Term Survival in Bone-Predominant Metastatic Urothelial Carcinoma.
- Role of Maximal Endoscopic Resection Before Cystectomy for Invasive Urothelial Bladder Cancer.
- Nonresponse to Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Cell Carcinoma of the Bladder.
- Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate Cancer (READY): a randomised, double-blind phase 3 trial.
- Castrate-resistant prostate Cancer: postdocetaxel management.
- A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate Cancer.
- Abiraterone in metastatic prostate Cancer without previous chemotherapy.
- Prostate Cancer: Bone density testing-essential or extraneous?
- Advanced clinical states in prostate Cancer.
- Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonm...
- Long-Term Dynamics of Bone Mineral Density During Intermittent Androgen Deprivation for Men With Nonmetastatic, Hormone-Sensitive Prostate Cancer.
- Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer.
- Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate Cancer.
- C11-acetate and F-18 FDG PET for men with prostate Cancer bone metastases: relative findings and response to therapy.
- Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate Cancer.
- Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate Cancer treated on a pros...
- Antitumour activity of MDV3100 in castration-resistant prostate Cancer: a phase 1-2 study.
- Phase II study of dasatinib in patients with metastatic castration-resistant prostate Cancer.
- Rapid clinical deterioration and leukemoid reaction after treatment of urothelial carcinoma of the Bladder: possible effect of granulocyte colony-stimulating factor.
- Positron emission tomography imaging as a Cancer biomarker.
- The origin of Cancer.
- Telomerase maintains telomere structure in normal human Cells.
- Neoadjuvant therapy for high-risk localized prostate Cancer.
- Lentivirus-deLivered stable gene silencing by RNAi in primary cells.
- Persistent androgen receptor addiction in castration-resistant prostate Cancer.
- Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder...
Schools
University of Washington
Brigham and Womens Hospital
Dana Farber Cancer InstPartners Cancer Care
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Brigham and Women's Hospital -
Stanford University -
University of Washington School of Medicine
Hospital
-
UW Medicine/Harborview Medical Center -
University of Washington Medical Center
Drug Facts
| NPI NUMBER | 1043390016 | |
| NPPES Provider LastName | YU | |
| NPPES Provider FirstName | EVAN | |
| NPPES Provider ZIPCode | 98109 | |
| NPPES Provider State | WA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 73.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1043390016 |
| Last Name Of The Provider | YU |
| First Name Of The Provider | EVAN |
| View All |
Similar Doctors
|
|
Dr. Mary L. Disis, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Joseph M. Weresch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Antonio A. Bedalov, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Maxwell M. Krem, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mazyar Shadman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Veena Shankaran, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Effie W. Petersdorf, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|